CBS-0550
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects. A number of related compounds have been developed with similar properties.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
CBS-0550
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects. A number of related compounds have been developed with similar properties.
has abstract
CBS-0550 is a drug developed b ...... loped with similar properties.
@en
CAS number
887289-02-3
FDA UNII code
TB180WQ919
PubChem
Wikipage page ID
35,446,279
page length (characters) of wiki page
Wikipage revision ID
963,741,896
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
23,320,245
IUPAC name
N-[5-tert-butyl-2--1-methylpyrazol-3-ylidene]-2-fluoro-3-benzamide
@en
PubChem
24,763,642
SMILES
C3CC3Cn1c=N\Cc2ccccc2F
@en
StdInChIKey
PABOWKPYVAFTRN-PCLIKHOPSA-N
@en
UNII
TB180WQ919
@en
wikiPageUsesTemplate
hypernym
comment
CBS-0550 is a drug developed b ...... loped with similar properties.
@en
label
CBS-0550
@en